Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]-PK11195 PET

Movement Disorders

Volumn 22, Issue 13, 2007, Pages 1852-1856

  Bartels, Anna L ^a   Leenders, Klaus L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

COX 2 inhibition; Microglia; Neuroinflammation; Neuroprotection; Parkinson's disease; PK11195 PET

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[25-35]; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBON 11; CYCLOOXYGENASE 2 INHIBITOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

BRAIN CORTEX; CEREBELLUM; DRUG EFFECT; DRUG MEGADOSE; ENCEPHALITIS; FRONTAL LOBE; HIPPOCAMPUS; HISTOCOMPATIBILITY COMPLEX; HUMAN; IN VIVO STUDY; MICROGLIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION MEDIATORS; ISOQUINOLINES; MICROGLIA; NERVE DEGENERATION; NITRIC OXIDE SYNTHASE TYPE II; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; REACTIVE OXYGEN SPECIES;

EID: 36249003354     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21552     Document Type: Review

References (41)

1. Korrell M, Tanner CM. Epidemiology of Parkinson's disease: an overview. In: Ebadi M, Pfeiffer R, editors. Parkinson's disease. Boca Raton, FL: CRC Press; 2005. p. 39-50.
2. Mcgeer PL, Mcgeer EG. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 1998;12:S1-S6.
3. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996;19:312-318.
4. Mcgeer PL, Itagaki S, Boyes BE, Mcgeer EG. Reactive microglia are positive for Hla-Dr in the substantia nigra of Parkinsons and Alzheimers-disease brains. Neurology 1988;38:1285-1291.
5. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003;106:518-526.
6. Zhou Y, Wang Y, Kovacs M, Jin JH, Zhang J. Microglial activation induced by neurodegeneration - a proteomic analysis. Molec Cell Proteomics 2005;4:1471-1479.
7. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 2003;341:87-90.
8. Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72:355-363.
9. Batchelor PE, Liberatore GT, Wong JYF, et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum sand express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999;19:1708-1716.
10. Zhang W, Wang TG, Pei Z et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005;19:533-542.
11. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
12. Mcgeer PL, Mcgeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Related Disorders 2004;10:S3-S7.
13. Gao HM, Hong JS, Zhang WQ, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002;22:782-790.
14. Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998;98:142-144.
15. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53:S49-S58.
16. Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 2005;193:279-290.
17. Przedborski S. Neuroinflammation in the MPTP mouse model and in Parkinson's disease. J Neurochem 2003;85:24.
18. Wu DC, Teismann P, Tieu K, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100:6145-6150.
19. Teismann P, Tieu K, Cohen O, et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003;18:121-129.
20. McGeer PL. NSAIDs and other antiinflammatory agents in the treatment of neurodegenerative and vascular diseases. Neurobiol Aging 2004;25:S18.
21. Chen HL, Zhang SMM, Hernan MA, et al. Nonsteroidal antiinflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-1064.
22. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58:963-967.
23. Ton TG, Heckbert SR, Longstreth WT, Jr., et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006;21:964-969.
24. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28:639-647.
25. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003;100:5473-5478.
26. Carrasco E, Casper D, Werner P. Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 2005;81:121-131.
27. Wang TG, Pei Z, Zhang W, et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 2005;19:1134-1136.
28. Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 2004;1:6.
29. Banati RB. Visualising microglial activation in vivo. Glia 2002;40:206-217.
30. Cagnin A, Gerhard A, Banati RB. In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 2002;12:581-586.
31. Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the enantiomers of [N-methyl-11 C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol 1994;21:573-581.
32. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002;15:991-998.
33. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168-175.
34. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [C-11](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006;21:404-412.
35. Pavese N, Gerhard A, Tai YF, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006;66:1638-1643.
36. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 2006;21:89-93.
37. Gerhard A, Banati RB, Cagnin A, Brooks DJ. In vivo imaging of activated microglia with [C-11]PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease. Neurology 2001;56:A270.
38. Gerhard A, Banati RB, Goerres GB et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003;61:686-689.
39. Gerhard A, Watts J, Trender-Gerhard I, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 2004;19:1221-1226.
40. Cagnin A, Brooks DJ, Kennedy AM, et al. In vivo detection of activated microglia in Alzheimer's disease: An [C-11](R)-PK11195 PET study. Neurology 2000;54:A476-A477.
41. Banati RB, Myers R, Kreutzberg GW. PK ('peripheral benzodiazepine')- binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [H-3]PK11195 binding to activated microglia. J Neurocytol 1997;26:77-82.